These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 631030)

  • 41. Relieving select symptoms of the elderly.
    Nelson JJ
    Geriatrics; 1975 Mar; 30(3):133-9, 142. PubMed ID: 803912
    [No Abstract]   [Full Text] [Related]  

  • 42. [Electroencephalography and psychometric measurements during the treatment of cerebral insufficiency with nicergoline and dihydroergotamine mesylate].
    Kugler JE; Meurer-Krüll BC
    Arzneimittelforschung; 1985; 35(12):1865-70. PubMed ID: 3913425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Functional improvement of the aging brain: placebo controlled pharmaco-EEG and psychometric studies with a metabolically active hemoderivative (Actovegin)].
    Saletu B; Grünberger J; Linzmayer L; Stöhr H
    Z Gerontol; 1984; 17(5):271-9. PubMed ID: 6395527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The treatment of senile dementia associated with cerebrovascular insufficiency: a comparative study of buflomedil and dihydrogenated ergot alkaloids.
    Jansen W; Bruckner GW; Jansen P
    J Int Med Res; 1985; 13(1):48-53. PubMed ID: 3884411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of intravenous high dose co-dergocrine mesylate ('Hydergine') in elderly patients with severe multi-infarct dementia: a double-blind, placebo-controlled trial.
    Arrigo A; Casale R; Giorgi I; Guarnaschelli C; Zelaschi F
    Curr Med Res Opin; 1989; 11(8):491-500. PubMed ID: 2680286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dihydroergotoxine: 6-mg versus 3-mg dosage in the treatment of senile dementia. Preliminary report.
    Yesavage JA; Hollister LE; Burian E
    J Am Geriatr Soc; 1979 Feb; 27(2):80-2. PubMed ID: 762369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia.
    Thienhaus OJ; Wheeler BG; Simon S; Zemlan FP; Hartford JT
    J Am Geriatr Soc; 1987 Mar; 35(3):219-23. PubMed ID: 3819261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydergine in senile mental impairment.
    Loew DM; Weil C
    Gerontology; 1982; 28(1):54-74. PubMed ID: 7037548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An ergot alkaloid preparation (hydergine) versus placebo for treatment of symptoms of cerebrovascular insufficiency: double-blind study.
    Jennings WG
    J Am Geriatr Soc; 1972 Aug; 20(8):407-12. PubMed ID: 4626496
    [No Abstract]   [Full Text] [Related]  

  • 50. [Experimental electropharmacologic studies of cerebral ischemia (author's transl)].
    Depoortere H
    Rev Electroencephalogr Neurophysiol Clin; 1981; 10(3):207-14. PubMed ID: 7302319
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sinus bradycardia following treatment with hydergine for cerebrovascular insufficiency.
    Dcayley AC; Macpherson A; Wedgwood J
    Br Med J; 1975 Nov; 4(5993):384-5. PubMed ID: 811310
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparison of the efficacy and safety of daily dosages of 6 mg and 20 mg dihydroergocristine in the treatment of chronic cerebro-vascular disease.
    Pagliano FM; Galbiati GC
    J Int Med Res; 1995; 23(4):219-27. PubMed ID: 7589764
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An ergot preparation (hydergine) in the treatment of cerebrovascular disorders in the geriatric patient: double-blind study.
    Ditch M; Kelly FJ; Resnick O
    J Am Geriatr Soc; 1971 Mar; 19(3):208-17. PubMed ID: 4998602
    [No Abstract]   [Full Text] [Related]  

  • 54. Effects of long-term ergoloid mesylates ('Hydergine') administration in healthy pensioners: 5-year results.
    Huber F; Köberle S; Prestele H; Spiegel R
    Curr Med Res Opin; 1986; 10(4):256-79. PubMed ID: 3780290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Drug-related increase of intelligence level. Considerations and a double-blind-study with flunarizin (sibelium) (author's transl)].
    Lehrl S; Sollberg G; Schumacher H
    Pharmakopsychiatr Neuropsychopharmakol; 1978 May; 11(3):134-46. PubMed ID: 353832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Methodology of a controlled trial of dihydroergotoxine in acquired intellectual impairment in the adult].
    Dartigues JF; Père JJ
    Presse Med; 1983 Dec; 12(48):3173-5. PubMed ID: 6228936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Treatment of cerebrovascular insufficiency. A trial of orphol in 8940 patients by 800 medical practitioners (author's transl)].
    Kukwa L
    MMW Munch Med Wochenschr; 1981 Feb; 123(8):310-4. PubMed ID: 6783887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo.
    Gaitz CM; Varner RV; Overall JE
    Arch Gen Psychiatry; 1977 Jul; 34(7):839-45. PubMed ID: 406875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of an ergot preparation (hydergine) in the convalescent phase of stroke.
    Bochner F; Eadie MJ; Tyrer JH
    J Am Geriatr Soc; 1973 Jan; 21(1):10-7. PubMed ID: 4630036
    [No Abstract]   [Full Text] [Related]  

  • 60. [Neuropsychologic evaluation of the action of oxovinca in the syndrome of diffuse deterioration of vascular origin (author's transl)].
    Jubert Gruart J; Navarra J; Canals R; Balaguer M
    Med Clin (Barc); 1980 Jul; 75(3):115-21. PubMed ID: 7401741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.